Med. praxi 2013; 10(11-12): 376-379 [Interní Med. 2013; 15(3-4): 94-98]

Venous thromboembolic disease and anticoagulant therapy in elderly patients

doc.MUDr.Dalibor Musil, Ph.D.
1 . interní klinika &ndash, kardiologická, Fakultní nemocnice Olomouc

The occurrence of venous thromboembolic disease (VTD) is very closely related to age. Elderly, hospitalized persons of both sexes are the

most vulnerable group. Acquired and external risk factors are involved to a greater degree here. Hereditary factors have a smaller effect

in comparison with young individuals. The diagnosis of VTD in the elderly is similar to that in other age groups; however, the proportion

of asymptomatic venous thromboses increases significantly in older age. The efficacy of oral anticoagulant therapy in elderly patients

is most influenced by their current clinical condition, their diet composition, including possible food supplements, and the medications

taken. The relationship between the risk of bleeding and the age during anticoagulant therapy is not unequivocal. There are papers

showing that elderly patients in whom anticoagulant therapy has been well adhered to, have the same risk of bleeding as young patients.

Following the introduction of low-molecular-weight heparins in the 1990s that allowed standard outpatient treatment of deep

vein thrombosis in many elderly patients, novel oral anticoagulants are another breakthrough development in the treatment of VTD.

Keywords: elderly patients, deep vein thrombosis, pulmonary embolism, epidemiology, risk factors, anticoagulant therapy, novel oral anticoagulants

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil D. Venous thromboembolic disease and anticoagulant therapy in elderly patients. Med. praxi. 2013;10(11-12):376-379.
Download citation

References

  1. Khorana AA, Spyropoulos AC, Zwicker J, Lyman GH, Francis CW. Preventing VTE in Outpatients With Cancer. Chest. 2012; 142: 265-266. Go to original source... Go to PubMed...
  2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: s. 933-938. Go to original source...
  3. Dostálová K, Štvrtinová V, Móricová S, Placka P. Venous thromboembolism in young adults. Int Angiol 2012; 31(Suppl. 1): s. 50-51.
  4. Di Minno G, Mannucci PM, Tufano A, et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost. 2005; 3: s. 1459-1466. Go to original source... Go to PubMed...
  5. Zöller B, Li X, Sundquist J, et al. Age-and gender-specific familial risks for venous thromboembolis. Circulation 2011; DOI 10.1161/circulationaha.110.965020. Go to original source... Go to PubMed...
  6. Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: s. 610-615. Go to original source... Go to PubMed...
  7. Kim DY, Kobavashi L, et al. Venous thromboembolism in the elderly: the result of comorbid conditions or a consequence of injury? J Trauma Acute Care Surg 2012; 72: s. 1286-1291. Go to original source... Go to PubMed...
  8. Bulger CM, Jacobs C, Patel NH. Epidemiology of acute deep venous thrombosis. Tech Vasc Interv Radiol 2004; 7: s. 50-54. Go to original source... Go to PubMed...
  9. Fogarty TJ, Krippaechne WW. Catheter technique for venous trombectomy. Surg Gynecol Obstetr 1965; 121: 362-364.
  10. Guyatt GH, Akl AE, Crowther M, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Free To View CHEST 2012; 141(2 suppl): 7S-47S. Go to original source...
  11. Gurnitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: s. 901-904. Go to original source... Go to PubMed...
  12. Wickrawasingle LS, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients. Age ageing 1987; 17: s. 388-396. Go to original source... Go to PubMed...
  13. Matýšková M. Warfarin, potrava a potravinové doplňky. Interní Med 2010; 12: 87-91.
  14. Fihn JD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicentric study. Ann Intern Med 1993; 118: s. 511-520. Go to original source... Go to PubMed...
  15. Ansell JE. Anticoagulation management as a risk factor for adverse events: ground for improvement. J Thromb Thrombolysis 1998; 5(suppl): S13-S18. Go to original source... Go to PubMed...
  16. McCormic D, Gurwit JH, Goldberg J, et al. Long-term anticoagulant therapy for atrial fibrillation in elderly patients: efficacy, risk, and current pattern of use. J Thromb Thrombolysis 1999; 7: 157-163. Go to original source... Go to PubMed...
  17. Prisco D, Cenci C, Silvestri E, Emmi G, Barnini T, Tamburini C. The risk stratification in atrial fibrillation. Intern Emerg Med. 2012; 7(Suppl 3): S233-240. Go to original source... Go to PubMed...
  18. Poli D, Antonucci E, Testa S, Tosetto A, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011; 124: 824-829. Go to original source... Go to PubMed...
  19. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrilation who are at risk for falls. Ann Pharmacother 2008; 42: s. 523-532. Go to original source... Go to PubMed...
  20. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-ranging study. Blood 2008; 112: s. 2242-2247. Go to original source... Go to PubMed...
  21. The EINSTEN investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: s. 2499-2510. Go to original source... Go to PubMed...
  22. The EINSTEIN-PE investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN-PE study. N Engl J Med 2012; 366: 1287-1297. Go to original source... Go to PubMed...
  23. Buller HR. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and EINSTEIN-PE studies. 54th American Society of Hematology annual meeting and exposition, Atlanta, GA, December 8-11 2012.
  24. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2353. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.